Date published: 2025-12-18

1-800-457-3801

SCBT Portrait Logo
Seach Input

WHI-P 154 (CAS 211555-04-3)

5.0(1)
Write a reviewAsk a question

See product citations (3)

Alternate Names:
2-Bromo-4-[(6,7-dimethoxy-4-quinazo linyl)amino]phenol
Application:
WHI-P 154 is a JAK3 inhibitor which inhibits other common kinases
CAS Number:
211555-04-3
Molecular Weight:
376.2
Molecular Formula:
C16H14BrN3O3
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.

QUICK LINKS

WHI-P 154 is a synthetic compound recognized for its role as a potent inhibitor of Janus kinases (JAKs), specifically targeting JAK3. This chemical exerts its effects by interfering with the ATP-binding site of the kinase, effectively blocking its enzymatic activity. Janus kinases are integral to the signaling pathways of various cytokines and growth factors, primarily involved in processes such as cell growth, survival, development, and differentiation. WHI-P 154′s mechanism of action involves the inhibition of JAK3, which disrupts the JAK-STAT signaling pathway, a critical pathway for the transduction of extracellular signals into the cell nucleus to modulate gene expression. By inhibiting this pathway, WHI-P 154 effectively reduces the transcriptional activation typically mediated by STAT proteins, thus impacting cellular responses to external signals. WHI-P 154 has been utilized to investigate the role of JAK-STAT signaling in various biological contexts. It has been particularly useful in studies focused on immunology and hematopoiesis, where JAK-STAT pathway plays a predominant role. By using this inhibitor, scientists can explore the effects of altered JAK-STAT signaling on immune cell function and development, contributing to a deeper understanding of immune regulation and the underlying mechanisms that control cellular responses to cytokines.


WHI-P 154 (CAS 211555-04-3) References

  1. Suppression of early T-cell-receptor-triggered cellular activation by the Janus kinase 3 inhibitor WHI-P-154.  |  Säemann, MD., et al. 2003. Transplantation. 75: 1864-72. PMID: 12811247
  2. Prevention of CD40-triggered dendritic cell maturation and induction of T-cell hyporeactivity by targeting of Janus kinase 3.  |  Säemann, MD., et al. 2003. Am J Transplant. 3: 1341-9. PMID: 14525593
  3. Inhibition of the antigen-induced activation of rodent mast cells by putative Janus kinase 3 inhibitors WHI-P131 and WHI-P154 in a Janus kinase 3-independent manner.  |  Linwong, W., et al. 2005. Br J Pharmacol. 145: 818-28. PMID: 15852029
  4. The JAK3 inhibitor WHI-P154 prevents PDGF-evoked process outgrowth in human neural precursor cells.  |  Richards, GR., et al. 2006. J Neurochem. 97: 201-10. PMID: 16515549
  5. JAK inhibitors AG-490 and WHI-P154 decrease IFN-gamma-induced iNOS expression and NO production in macrophages.  |  Sareila, O., et al. 2006. Mediators Inflamm. 2006: 16161. PMID: 16883061
  6. Janus kinase 3 inhibitor WHI-P154 in macrophages activated by bacterial endotoxin: differential effects on the expression of iNOS, COX-2 and TNF-alpha.  |  Sareila, O., et al. 2008. Int Immunopharmacol. 8: 100-8. PMID: 18068105
  7. WHI-P154 enhances the chemotherapeutic effect of anticancer agents in ABCG2-overexpressing cells.  |  Zhang, H., et al. 2014. Cancer Sci. 105: 1071-8. PMID: 24903205
  8. Regulation of Voltage Gated K+ Channel KCNE1/KCNQ1 by the Janus Kinase JAK3.  |  Warsi, J., et al. 2015. Cell Physiol Biochem. 37: 2476-85. PMID: 26666518
  9. Down-Regulation of Store-Operated Ca2+ Entry and Na+ Ca2+ Exchange in MCF-7 Breast Cancer Cells by Pharmacological JAK3 Inhibition.  |  Yan, J., et al. 2016. Cell Physiol Biochem. 38: 1643-51. PMID: 27119652

Ordering Information

Product NameCatalog #UNITPriceQtyFAVORITES

WHI-P 154, 10 mg

sc-204395
10 mg
$150.00

WHI-P 154, 50 mg

sc-204395A
50 mg
$630.00